期刊文献+

血清基质金属蛋白酶-3、-9的检测及其与系统性红斑狼疮活动性的关系 被引量:8

The relationship between the serum level of MMP-3 and MMP-9 and the activity of systemic lupus erythematosus
下载PDF
导出
摘要 目的:探讨基质金属蛋白酶(MMP)-3、MMP-9以及金属蛋白酶组织抑制因子(TIMP)-1在系统性红斑狼疮(SLE)发病机制中的作用和意义。方法:采取双抗体夹心ELISA法检测45例SLE患者及30名正常对照者血清MMP-3、MMP-9及TIMP-1水平。结果:①与正常对照者相比,患者血清MMP-3水平明显增高(P<0.01),而血清MMP-9水平明显降低(P<0.01);经糖皮质激素治疗后血清MMP-3水平下降(P<0.01),血清MMP-9水平升高(P<0.01);②SLE患者活动组、抗ds-DNA抗体阳性组、低C3血症者、低血清白蛋白血症者血清MMP-3水平高于对照组(P<0.05),而MMP-9水平低于对照组(P<0.05);SLE患者肾损害组、肺炎组患者血清MMP-3水平高于无上述表现者(P<0.01),而MMP-9水平低于无上述表现者(P<0.01);③血清TIMP-1水平在SlE组与对照组、SLE相关各组间差异均无统计学意义;④SLE患者血清MMP-3水平与SLE疾病活动指数(SLEDAI)呈正相关(P<0.01),MMP-9水平与SIEDAI呈负相关(P<0.01)。结论:MMP-3及MMP-9可能参与SLE发病机制。 Objective: To explore the clinical significance of serum matrix metalloproteinase-3(MMP-3), matrix metallopro-teinase-9 (MMP-9) and tissue inhibitor of metalloproteinase-1(TIMP-1) in patients with systemic lupus erythematosus (SLE). Methods: The serum level of MMP-3, MMP-9 and TIMP-1 were measured by ELISA in SLE patients and healthy controls. Results: ① The serum level of MMP-3 in SLE patients was significantly higher as compared with that in healthy controls (P〈 0.01), while the MMP-9 level in SLE patients was decreased (P〈 0.01). After treatment with glucocorticosteroid serum MMP-3 levels decreased markedly (P〈 0.01), but the MMP-9 levels increased (P〈 0.01); ② In the patients with active SLE, decreased C3 levels, hypoalbuminemia or anti-ds-DNA positive, serum MMP-3 levels were higher and MMP-9 were lower than the normal controls (P〈 0.05). MMP-3 levels in patients with renal or pulmonary involvement were respectively higher than those patients without the corresponding involvements (P〈 0.01), and MMP-9 were lower (P〈 0.01); ③Serum TIMP-1 levels did not show significant difference between the SLE patients and healthy controls and within the different SLE groups; ④In SLE patients, a significantly positive correlation betwen MMP-3 levels and SLEDAI scores was found (P 〈 0.01), but serum MMP-9 levels and SLEDAI scores were negatively correlated (P 〈 0.01). Conclution: MMP-3 and MMP-9 are probably involved in the pathogenesis of SLE, which may be used as indicators to moitor disease activity, renal damage, disease progression and improvement in SLE .
出处 《临床皮肤科杂志》 CAS CSCD 北大核心 2007年第9期556-558,共3页 Journal of Clinical Dermatology
关键词 红斑狼疮 系统性 基质金属蛋白酶类 金属蛋白酶组织抑制因子-1 lupus erythematosus, systemic matrix metalloproteinases tissue inhibitor of metalloproteinase-1
  • 相关文献

参考文献8

  • 1Kotajima L,Aotsuka S,Fujimani M,et al.Increased levels of matrix metalloproteinase-3 in sera from patients with active lupus nephritis[J].Clin Exp Rheumatol,1998,16(4):409-415.
  • 2Zucker S,Mian N,Drews M,et al.Increased serum stromelysin-1 levels in systemic lupus erythematosus:lack of correlation with disease activity[J].J Rheumatol,1999,26(1):78-80.
  • 3殷文浩,鲍彰,郑敏.系统性红斑狼疮患者血清基质金属蛋白酶-9的检测[J].中华皮肤科杂志,2004,37(2):77-79. 被引量:5
  • 4刘暘,郑敏,殷文浩,鲍彰.血清基质金属蛋白酶-9检测与系统性红斑狼疮活动性的关系[J].中华风湿病学杂志,2004,8(4):220-222. 被引量:4
  • 5Zucker S,Hymowitz M,Conner C,et al.Measurement of matrix metalloproteinases and tissue inhibitors of metalloproteinases in blood and tissues.Clinical and experimental applications[J].Ann NY Acad Sci,1999,878:212-227.
  • 6Faber-Elmann A,Sthoeger Z,Tcherniack A,et al.Activity of matrix metalloproteinase-9 is elevated in sera of patients with systemic lupus erythematosus[J].Clin Exp Immunol,2002,127(2):393-398.
  • 7Ainiala H,Hietaharju A,Dastidar P,et al.Increased serum matrix metalloproteinase 9 levels in systemic lupus erythematosus patients with neuropsychiatric manifestations and brain magnetic resonance imaging abnormalities[J].Arthritis Rheum,2004,50(3):858-865.
  • 8Suga M,Iyonaga K,Okamoto T,et al.Characteristic elevation of matrix metalloproteinase activity in idiopathic interstitial pneumonias[J].Am J Respir Crit Care Med,2000,162(5):1949-1956.

二级参考文献13

  • 1American College of Rheumatology Ad Hoc Committee on Systemic Lupus Erythematosus.Guidelines for referral and management of systemic lupus erythematosus in adults. Arthritis Rheum,1999,42:1785-1796.
  • 2Bombardier C,Gladman DD,Urouritz MB,et al. Derivation of the SLEDAI,disease activity index for lupus patients.The Cmmittee on rognosis Studies in SLE.Arthritis Rheum, 1992,35:630-640.
  • 3Sato Y,Fujimoto S,Hamai K,et al. Serial alterations of glomerular matrix-degrading metalloproteinase activity in anti-thymocyteinduced glomerulonephritis in rats.Nephron,1998,78:195-200.
  • 4Faber-Elmann A,Eilat E,Zinger H,et al.A peptide based on antiDNA autoantibody down regulates matrix metalloproteinase. ClinImmunol,2002,105:223 -232.
  • 5Sharif M,Salisbury C,Taylor DJ,et al.Changes in biochemical markers of joint tissue metabolism in a randomized controlled trial of glucocorticoid in realy rheumatoid arthritis. Arthritis Rheum,1998,41:1203-1209.
  • 6Bombardier C, Gladman DD, Urowitz MB, et al. Derivation of the SLEDAI. A disease activity index for lupus patients. The Committee on Prognosis Studies in SLE. Arthritis Rheum, 1992, 35:630-640.
  • 7Takeshita S, Tokutomi T, Kawase H, et al. Elevated serum levels of matrix metalloproteinase-9 (MMP-9) in Kawasaki disease. Clin Exp Immunol, 2001, 125:340-344.
  • 8Faber-Elmann A, Sthoeger Z, Tcherniack A, et al. Activity of matrix metalloproteinase-9 is elevated in sera of patients with systemic lupus erythematosus. Clin Exp Immunol, 2002, 127:393-398.
  • 9Zucker S, Hymowitz M, Conner C, et al. Measurement of matrix metalloproteinases and tissue inhibitors of metalloproteinases in blood and tissues. Clinical and experimental applications. Ann N Y Acad Sci, 1999, 878:212-27.
  • 10Kjeldsen L, Bjerrum OW, Hovgaard D, et al. Human neutrophil gelatinase: a marker for circulating blood neutrophils. Purification and quantitation by enzyme linked immunosorbent assay. Eur J Haematol, 1992, 49:180-191.

共引文献7

同被引文献52

引证文献8

二级引证文献21

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部